Your browser doesn't support javascript.
Diagnosis of SARS-CoV-2 Infection with LamPORE, a High-Throughput Platform Combining Loop-Mediated Isothermal Amplification and Nanopore Sequencing.
Peto, Leon; Rodger, Gillian; Carter, Daniel P; Osman, Karen L; Yavuz, Mehmet; Johnson, Katie; Raza, Mohammad; Parker, Matthew D; Wyles, Matthew D; Andersson, Monique; Justice, Anita; Vaughan, Alison; Hoosdally, Sarah; Stoesser, Nicole; Matthews, Philippa C; Eyre, David W; Peto, Timothy E A; Carroll, Miles W; de Silva, Thushan I; Crook, Derrick W; Evans, Cariad M; Pullan, Steven T.
  • Peto L; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom leon.peto@ndm.ox.ac.uk.
  • Rodger G; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Carter DP; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Osman KL; Public Health England, National Infection Service, Salisbury, United Kingdom.
  • Yavuz M; Public Health England, National Infection Service, Salisbury, United Kingdom.
  • Johnson K; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
  • Raza M; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
  • Parker MD; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
  • Wyles MD; Sheffield Biomedical Research Centre, Sheffield Bioinformatics Core, University of Sheffield, Sheffield, United Kingdom.
  • Andersson M; Sheffield Biomedical Research Centre, Sheffield Bioinformatics Core, University of Sheffield, Sheffield, United Kingdom.
  • Justice A; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Vaughan A; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Hoosdally S; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Stoesser N; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Matthews PC; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Eyre DW; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Peto TEA; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Carroll MW; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • de Silva TI; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Crook DW; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Evans CM; Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
  • Pullan ST; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
J Clin Microbiol ; 59(6)2021 05 19.
Article in English | MEDLINE | ID: covidwho-1158099
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
LamPORE is a novel diagnostic platform for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA combining loop-mediated isothermal amplification with nanopore sequencing, which could potentially be used to analyze thousands of samples per day on a single instrument. We evaluated the performance of LamPORE against reverse transcriptase PCR (RT-PCR) using RNA extracted from spiked respiratory samples and stored nose and throat swabs collected at two UK hospitals. The limit of detection of LamPORE was 10 genome copies/µl of extracted RNA, which is above the limit achievable by RT-PCR, but was not associated with a significant reduction of sensitivity in clinical samples. Positive clinical specimens came mostly from patients with acute symptomatic infection, and among them, LamPORE had a diagnostic sensitivity of 99.1% (226/228; 95% confidence interval [CI], 96.9% to 99.9%). Among negative clinical specimens, including 153 with other respiratory pathogens detected, LamPORE had a diagnostic specificity of 99.6% (278/279; 98.0% to 100.0%). Overall, 1.4% (7/514; 0.5% to 2.9%) of samples produced an indeterminate result on first testing, and repeat LamPORE testing on the same RNA extract had a reproducibility of 96.8% (478/494; 94.8% to 98.1%). LamPORE has a similar performance as RT-PCR for the diagnosis of SARS-CoV-2 infection in symptomatic patients and offers a promising approach to high-throughput testing.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanopore Sequencing / COVID-19 Type of study: Diagnostic study / Experimental Studies / Prognostic study Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: JCM.03271-20

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanopore Sequencing / COVID-19 Type of study: Diagnostic study / Experimental Studies / Prognostic study Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: JCM.03271-20